CeriBell (NASDAQ:CBLL - Free Report) - William Blair cut their Q1 2025 earnings per share (EPS) estimates for shares of CeriBell in a research note issued to investors on Wednesday, February 26th. William Blair analyst M. Andrew now forecasts that the company will post earnings per share of ($0.44) for the quarter, down from their previous estimate of ($0.30). William Blair currently has a "Outperform" rating on the stock. The consensus estimate for CeriBell's current full-year earnings is ($2.46) per share. William Blair also issued estimates for CeriBell's Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.81) EPS, Q1 2026 earnings at ($0.37) EPS, Q2 2026 earnings at ($0.35) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.33) EPS and FY2026 earnings at ($1.40) EPS.
CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The business had revenue of $18.53 million for the quarter, compared to analysts' expectations of $17.55 million.
Other equities analysts have also recently issued reports about the company. Canaccord Genuity Group began coverage on CeriBell in a report on Tuesday, November 5th. They issued a "buy" rating and a $30.00 target price for the company. Bank of America assumed coverage on CeriBell in a report on Tuesday, November 5th. They set a "buy" rating and a $32.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set an "overweight" rating and a $32.00 target price for the company. Canaccord Genuity Group restated a "buy" rating and issued a $33.00 price target on shares of CeriBell in a research report on Wednesday, February 26th. Finally, TD Cowen upped their price objective on shares of CeriBell from $31.00 to $36.00 and gave the stock a "buy" rating in a research note on Monday, December 9th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, CeriBell currently has a consensus rating of "Buy" and an average target price of $32.60.
Get Our Latest Report on CeriBell
CeriBell Stock Down 3.5 %
NASDAQ:CBLL traded down $0.86 during mid-day trading on Friday, hitting $23.76. The company's stock had a trading volume of 346,836 shares, compared to its average volume of 197,588. The company has a fifty day simple moving average of $23.22. CeriBell has a fifty-two week low of $18.69 and a fifty-two week high of $32.75.
Institutional Investors Weigh In On CeriBell
Hedge funds have recently added to or reduced their stakes in the stock. FMR LLC bought a new position in CeriBell in the 4th quarter worth approximately $128,120,000. TPG GP A LLC acquired a new stake in shares of CeriBell in the 4th quarter valued at $102,677,000. Red Tree Management LLC bought a new stake in shares of CeriBell during the fourth quarter worth $57,083,000. Yu Fan acquired a new position in shares of CeriBell during the fourth quarter valued at $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd bought a new position in CeriBell in the fourth quarter valued at about $28,160,000.
About CeriBell
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Featured Stories
Before you consider CeriBell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.
While CeriBell currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
